Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA investigating Matria Healthcare, other firms, for subcutaneous infusion of terbutaline.

This article was originally published in The Gray Sheet

Executive Summary

FDA INVESTIGATING TERBUTALINE DELIVERY VIA INFUSION PUMPS BY MATRIA, OTHER FIRMS, the agency notes in its response to a National Women's Health Network's petition to enjoin Matria Healthcare from marketing and distributing subcutaneous infusion pumps for the management of preterm labor. The agency reports that it is "investigating the activities of Matria and other providers of home health care services" with respect to their promoting terbutaline for preventing preterm labor.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel